Navigation Links
SleepQuest to Open San Francisco Office
Date:7/1/2008

SAN FRANCISCO, July 1 /PRNewswire/ -- Finding relief from Obstructive Sleep Apnea (OSA) just got easier with the opening of SleepQuest's newest location in San Francisco. "We are excited to be opening a new office," said Robert Koenigsberg, President/CEO of SleepQuest, Inc. "We are well known throughout the Bay Area and many doctors and medical groups have requested that we set up an office there."

SleepQuest works closely with physicians and insurance groups around the Bay Area. For more than 10 years, SleepQuest has helped thousands of patients get a restful night's sleep. "We are the preferred provider for many insurance plans in the Bay Area and have a very strong working relationship with both primary care doctors and specialists such as ENTs and Pulmonologists," Koenigsberg said. "We work closely with physicians, sleep labs and managed care groups who direct patient care with HMO plans."

Looking to better serve a diverse population, SleepQuest translates many of its forms and literature into Spanish and Chinese. To further bridge the language barrier in San Francisco, SleepQuest welcomes Justina Yu as the San Francisco Field Office Supervisor. "Bilingual services benefit all patients, and my ability to communicate with Chinese speaking patients and family members should give them a better understanding and higher comfort level for the testing and treatment process," Yu said.

Although OSA is mostly a middle-age condition, it can also affect small children. "We have a commitment to helping patients of all ages and by opening this office we can greatly increase the number of services we provide by being closer to our patients who live in San Francisco," Koenigsberg said.

SleepQuest's services require a doctor's prescription. SleepQuest will then work with the patient to verify insurance eligibility before conducting testing or beginning treatment. "Doctors choose to work with us because we are successful in obtaining CPAP compli
'/>"/>

SOURCE SleepQuest
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. SleepQuest Launches Updated Web Site
2. SleepQuest Raises Awareness of Sleep Disorders
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
5. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
6. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
7. Osteotech to Present at Sidoti Conference in San Francisco
8. IDM Pharma to Present at BIO InvestorForum in San Francisco
9. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
10. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
11. The American Fertility Association Brings Fertility Education to San Francisco or Parent Hopefuls - Straight and Gay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Kitware, a leader ... tool that enables the exploration of hospital costs ... in response to the recent release of “Medicare Provider ... top 100 most-billed procedures from the Centers for Medicare ... for similar procedures at hospitals across the country has ...
(Date:5/17/2013)... May 17, 2013 Topricin Pain ... Inc., has been listed among nationally recommended over-the-counter ... initiative conducted by "U.S. News" Health in collaboration ... the “No. 1 Pharmacists Recommended designation” in ... national OTC brands, and is the only homeopathic ...
(Date:5/17/2013)... world-leading provider of scientific, technical and medical information products ... study in Reproductive BioMedicine Online ... an abnormal chromosomal composition can be identified by the ... classifying the risk of genetic abnormality without a biopsy. ... a retrospective study, using their predictive model to assess ...
(Date:5/17/2013)... , May 17, 2013  Yongye International, Inc. (NASDAQ: ... leading developer, manufacturer, and distributor of crop nutrient products ... , today announced that, on May 16, 2013, the ... directors (the "Board of Directors") was provided a letter ... Hong Kong ) Limited ("Abax") to Full Alliance ...
Breaking Biology Technology:Kitware Enables Interactive Exploration of CMS Medicare Data 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Breakthrough for IVF? 2Breakthrough for IVF? 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... 5 , - Data Presented ... York , ThromboGenics NV (Euronext Brussels: ... innovative medicines for eye,disease, vascular disease and cancer, today announces ... the treatment of,Diabetic Macular Edema (MIVI II DME). The data ...
... , LA JOLLA, Calif., Oct. 5 Transdel Pharmaceuticals, Inc. ... a conference call and audio webcast on Tuesday, October 6, ... of its Phase 3 clinical study for Ketotransdel®, a topical ... A press release will be issued on Tuesday, October 6, ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
Cached Biology Technology:ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 4Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 2Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4
(Date:5/19/2013)... have engineered a strain of electricity-producing bacteria that can ... and carbon dioxide as its sole source of carbon. ... their findings at the 113th General Meeting of the ... result of current production solely on hydrogen," says Amit ... his co-authors are part of the Lovley Lab Group ...
(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... a mile below the ocean surface donot bother ... to one spot. Fornourishment, they rely completely onsymbiotic ... sulphurous volcanicsoup in which they both thrive. , ... bacteria-free, with a completedigestive system. Juveniles swim, hunt, ...
... in some animals to periodically wake up while hibernating may ... researchers at Penn State. The finding could offer an insight ... and has potential implications for human health. , ... part of a unique strategy to get past harsh winters ...
... It may be possible to protect the testes of cancer ... scientist told the 22nd annual conference of the European Society ... Tuesday 20 June 2006. Mr. Alon Carmely from ... for the first time that the injection of a drug ...
Cached Biology News:Giant deep-sea tubeworm's meal ticket comes in as a skin infection 2Giant deep-sea tubeworm's meal ticket comes in as a skin infection 3Breaks in hibernation help fight bugs 2Injection may prevent infertility in men receiving cancer chemotherapy 2
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
... all types of yeast two-hybrid studies, including complex interaction ... Choice of two bait vectors for maximum flexibility ... Triple reporter strain NMY51 ensures ... Complete set of controls: pLexA-p53, pLexA-lamin C ...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Biology Products: